|
Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus |
Rotavirus Vaccine |
103477 |
NCT00169455 |
Infections, Rotavirus |
Phase 3 |
|
|
|
|
An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies. |
January 2014 |